Medical/Pharmaceuticals
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome
YANTAI, China, Jan. 24, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, recently announced positive results from the completion of its Phase II trial inChina for Telitacicept in the treatment of primary Sjögren's syndrome ("pSS"). A total of 42 patient...
2022-01-25 09:00
4394
ImmVira's New-Generation Vector Poised to Enable CAR-T Treatment for Solid Tumors
SHENZHEN, China, Jan. 24, 2022 /PRNewswire/ -- Demonstrating innovation leadership on a global level, ImmVira announced that, its custom-designed new-generation oncolytic herpes simplex virus ("oHSV") vector enabling CAR-T treatment for solid tumors has started pilot-scale manufacturing and Phar...
2022-01-25 08:30
2182
IMPRESSION Randomized Trial: Past the halfway mark and progressing rapidly
SINGAPORE, Jan. 24, 2022 /PRNewswire/ -- Concept Medical Inc.,
2022-01-24 23:35
4310
Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826("p...
2022-01-24 21:47
3342
MGI's New MGISP-Smart 8 Automated Sample Preparation System Makes International Debut at MEDLAB Middle East
DUBAI, UAE, Jan. 24, 2022 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a global life science leader and innovator, has unveiled its new MGISP-Smart 8 automated sample preparation system to the world at MEDLAB Middle East, which kicked off today at the Dubai World Trade Center. The event marks the ...
2022-01-24 19:30
2264
MGI's New MGISP-Smart 8 Automated Sample Preparation System Makes International Debut at MEDLAB Middle East
DUBAI, UAE, Jan. 24, 2022 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a global life science leader and innovator, has unveiled its new MGISP-Smart 8 automated sample preparation system to the world at MEDLAB Middle East, which kicked off today at the Dubai World Trade Center. The event marks the ...
2022-01-24 19:30
2192
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2021 Financial Results
* Q4'21 revenue of KRW 444.3 billion increased 18% compared to Q4'20. * Q4'21 operating profit of KRW 128.8 billion increased 39% compared to Q4'20. * FY'21 revenue of KRW 1,568.0 billion, an increase of 35% compared to FY'20. * FY'21 operating profit of KRW 537.3 billion, an increase of 84% ...
2022-01-24 16:25
2994
Harbour BioMed Announces Dosing of First Patient in Combination Therapy Phase Ib/IIa Trial of Next-Generation Anti-CTLA-4 Antibody
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, it has successfully completed the dosing of first patient in phase Ib/IIa trial at the stage of dose expansion of its anti-CTLA-4 antibody (HBM4003) in ...
2022-01-24 15:39
2527
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2022-01-24 15:22
5463
Applied Pharmaceutical Science Inc. Announces FDA Approval of Investigational New Drug Application for APS03118, a Next generation RET Original New Drug for Unlimited Cancers
BEIJING and PHILADELPHIA, Jan. 24, 2022 /PRNewswire/ -- Applied Pharmaceutical Science, Inc. ("APS" or "the Company"), has recently announced the Investigational New Drug (IND) application for its self-developed breakthrough new drug APS03118, a next generation selective RET inhibitor, has been a...
2022-01-24 13:10
3907
New York Medical Group Publishes Research on Tech Neck
NEW YORK, Jan. 24, 2022 /PRNewswire/ -- New York Medical Group
2022-01-24 12:39
2566
Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
HANGZHOU and SHAOXING, China, Jan. 23, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). ASC40 is an oral, sele...
2022-01-23 18:35
5329
Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma at ASCO GI Annual Meeting 2022
SAN FRANCISCO and SUZHOU, China, Jan. 22, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2022-01-22 08:00
9493
Swiss Pharma Company - IDEOGEN takes over Special Access Program for BELEODAQ® (belinostat)
HURDEN, Switzerland, Jan. 22, 2022 /PRNewswire/ -- IDEOGEN GROUP, Managed Access division, takes over Special Access Program for BELEODAQ® (belinostat) in Europe, Middle East, North Africa, Russia, and CIS. BELEODAQ® is a prescription medicine used to treat patients with a rare form of blood canc...
2022-01-22 04:24
5316
ELEVAI LABS, INC. ANNOUNCES GLOBAL DISTRIBUTION PARTNERSHIP WITH PREMIER AESTHETIC DEVICE COMPANY DERMAPENWORLD
DAVIS, Calif., Jan. 21, 2022 /PRNewswire/ -- ELEVAI LABS, INC., ("ELEVAI" or the "Company") a biotech company leveraging the power of human stem cell exosomes to create next-generation topical skincare products, is pleased to announce that it has signed a non-exclusive global distributor and trad...
2022-01-21 13:41
2302
Sihuan Pharmaceutical (0460.HK): Establishment of Joint Venture with Bluepha Co., Ltd.
HONG KONG, Jan. 21, 2022 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group:" Hong Kong Stock Exchange Stock Code: 0460) is pleased to announce thatBeijing MeiYan KongJian...
2022-01-21 11:12
6705
Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an orally bioavailable Chimeric Degrader targeting Androgen Receptor for Prostate Cancer Treatment
MELBOURNE, Australia, Jan. 21, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, announced that the first patient with metastat...
2022-01-21 05:30
2993
Suvoda Exceeds 2021 Targets; Poised for Continued Growth Supporting Complex Clinical Trials in 2022
Surpasses 900 trials across 65 countries, expands leadership team and product offerings, and posts another year of 30% growth, all while maintaining an exceptional performance level. PHILADELPHIA, Jan. 20, 2022 /PRNewswire/ -- Suvoda, LLC, a global clinical trial technology company that speciali...
2022-01-20 23:05
2941
HanAll Biopharma Reports Full-Year 2021 Results and Provides Business Update
* 2021 sales of KRW 101.6 billion for a 15% increase from 2020 * 2021 operating profit of KRW 10.1 billion grew by 70% from 2020 * Increasing milestone payments and revenues from R&D activities are reinvested into new R&D programs SEOUL, South Korea, Jan. 20, 2022 /PRNewswire/ -- [Busines...
2022-01-20 22:00
3013
Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomas
AUSTIN, Texas, Jan. 20, 2022 /PRNewswire/ --VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the results of two large scale clinical studies, which show that the company's Nu.Q® assays, when used in conjunction with the Fecal Immunochemica...
2022-01-20 21:30
4232
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 273 media titles]
2026-10-09 13:21Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 263 media titles]
2026-10-05 11:51Most Read
RoboParty Unveils RP1, a High-Performance Full-Stack Open-Source Humanoid Robot at IROS
2026-10-04 00:56
10232
Nuix Neo Generative AI Framework
2026-10-08 08:02
8768
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
7667
